These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 26842127)

  • 1. Lessons learned from cancer vaccine trials and target antigen choice.
    Butterfield LH
    Cancer Immunol Immunother; 2016 Jul; 65(7):805-12. PubMed ID: 26842127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen-specific vaccines for cancer treatment.
    Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer vaccines.
    Butterfield LH
    BMJ; 2015 Apr; 350():h988. PubMed ID: 25904595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAGE-A3: an immunogenic target used in clinical practice.
    Esfandiary A; Ghafouri-Fard S
    Immunotherapy; 2015; 7(6):683-704. PubMed ID: 26100270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [NY-ESO-1 and cancer immunotherapy].
    Peng JR; Leng XS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA vaccine for cancer immunotherapy.
    Yang B; Jeang J; Yang A; Wu TC; Hung CF
    Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
    Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
    Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor vaccine: current trends in antigen specific immunotherapy.
    Baral R
    Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer vaccines and immunotherapies: emerging perspectives.
    Henderson RA; Mossman S; Nairn N; Cheever MA
    Vaccine; 2005 Mar; 23(17-18):2359-62. PubMed ID: 15755628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor antigens as surrogate markers and targets for therapy and vaccines.
    Dalgleish A; Pandha H
    Adv Cancer Res; 2007; 96():175-90. PubMed ID: 17161680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
    Seremet T; Brasseur F; Coulie PG
    Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Epitope peptide vaccine with oncoantigen for cancer and its biomarker].
    Hazama S; Maeda K; Oka M
    Nihon Rinsho; 2012 Dec; 70(12):2189-93. PubMed ID: 23259395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current perspectives on immunotherapy.
    Weber JS
    Semin Oncol; 2014 Oct; 41 Suppl 5():S14-29. PubMed ID: 25438996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer vaccines: what do we need to measure in clinical trials?
    Kudrin A
    Hum Vaccin Immunother; 2014; 10(11):3236-40. PubMed ID: 25483508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical cancer vaccine trials.
    Jäger E; Jäger D; Knuth A
    Curr Opin Immunol; 2002 Apr; 14(2):178-82. PubMed ID: 11869889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].
    Sawada Y; Nakatsura T
    Nihon Rinsho; 2012 Dec; 70(12):2136-41. PubMed ID: 23259386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
    Bioley G; Guillaume P; Luescher I; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Valmori D; Ayyoub M
    Clin Cancer Res; 2009 Jan; 15(1):299-306. PubMed ID: 19118058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Therapeutic Cancer Vaccines.
    Wong KK; Li WA; Mooney DJ; Dranoff G
    Adv Immunol; 2016; 130():191-249. PubMed ID: 26923002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.